Atopix Therapeutics' Debt Round

Atopix Therapeutics raised a round of funding on June 17, 2015. Investors include Silicon Valley Bank.

Atopix Therapeutics is a privately held clinical-stage biopharmaceutical company that is developing a class of oral anti-allergic medicines, called CRTH2 antagonists, to treat atopic dermatitis, asthm…

Articles about Atopix Therapeutics' Debt Round: